Pava Partners advised the shareholders of Genedata AG (“Genedata”), a leading provider of software solutions for biopharmaceutical R&D, on the sale to Danaher Corporation (NYSE: DHR) (“Danaher”), a leading global life sciences and diagnostics innovator.

This strategic acquisition presents an exciting opportunity for Genedata and Danaher to draw on their complementary strengths to drive life sciences innovation further. Genedata will operate as a standalone operating company and brand within Danaher’s Life Sciences segment. Genedata’s offerings are expected to add to Danaher’s broad workflow solutions that help accelerate the speed of drug discovery, development, and manufacturing for critical new therapies.

Founded in 1997 and headquartered in Basel, Switzerland, Genedata is at the forefront of transforming data into intelligence for the life sciences industry. Genedata delivers scalable and open solutions that enhance R&D productivity, serving top global biopharmaceutical companies and innovative biotechnology organizations around the globe. Over the last few years, and prior to this transaction, Genedata and Danaher have engaged in several successful collaborations.

“Genedata is a global market leader in digitalizing R&D processes to help accelerate the delivery of lifesaving and personalized medicines. Our achievements are driven by the dedication and expertise of our teams, whose efforts have been instrumental in earning the trust of our customers,” said Othmar Pfannes, Ph.D., Founder and CEO of Genedata. “As a Danaher operating company, Genedata will seek to continue to attract the brightest talent and solve our customers’ hardest problems globally.”

“Throughout our trusted relationship with Genedata, we have long admired their innovative software systems anchored in deep scientific expertise. We share a commitment to supporting biopharma companies to accelerate the development of much-needed therapies by providing innovative solutions that help researchers access high-quality insights,” said Greg Milosevich, Vice President and Group Executive of Danaher’s DH Life Sciences LLC subsidiary. “We are excited to welcome their team to Danaher and intend to continue expanding Genedata’s capabilities to address new technologies and requirements in this quickly evolving field.”